Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 10/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 9/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10241656 | 0.93 | HCRTR2 (0.43) | HCRTR2HCRTR1KCNH2TSHRSMN1; SMN2 | |
| SCHEMBL10239683 | 0.89 | HCRTR2 (0.41) | HCRTR2HCRTR1KCNH2 | |
| SCHEMBL10239953 | 0.88 | HCRTR2 (0.42) | HCRTR2HCRTR1KCNH2TSHRSMN1; SMN2 | |
| SCHEMBL10239720 | 0.87 | HCRTR1 (0.34) | HCRTR2HCRTR1KCNH2TSHRSMN1; SMN2 | |
| SCHEMBL10239944 | 0.85 | HCRTR2 (0.40) | HCRTR2HCRTR1TSHRSMN1; SMN2GAA | |
| SCHEMBL10241598 | 0.85 | HCRTR1 (0.35) | HCRTR2HCRTR1KCNH2SMN1; SMN2POLB | |
| SCHEMBL10239681 | 0.85 | HCRTR2 (0.51) | HCRTR2HCRTR1KCNH2TSHRSMN1; SMN2 | |
| SCHEMBL10240707 | 0.84 | HCRTR2 (0.41) | HCRTR2HCRTR1SMN1; SMN2POLBALDH1A1 | |
| SCHEMBL10266452 | 0.83 | HCRTR1 (0.53) | HCRTR2HCRTR1KCNH2 | |
| SCHEMBL10241665 | 0.82 | HCRTR2 (0.65) | HCRTR2HCRTR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | HCRTR2, HCRTR1, CNR1 | HCRTR2 1/4885HCRTR1 2/4885KCNH2 1409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.